ArticleThe Prostate2008
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.
Article in The Prostate, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 60 citations in OpenAlex.
- Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.Investigational new drugs · 2019Trial
- Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2013Trial
- Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.Clinical genitourinary cancer · 2012Trial
- Review
- From Therapy Resistance to Targeted Therapies in Prostate Cancer.Frontiers in oncology · 2022Review
- Drug repositioning by merging active subnetworks validated in cancer and COVID-19.Scientific reports · 2021Article
- Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.Pharmaceutics · 2021Review
- Role of Altered Metabolic Microenvironment in Osteolytic Metastasis.Frontiers in cell and developmental biology · 2020Review
- Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.Frontiers in oncology · 2018Review
- Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.Oncotarget · 2016Article
- Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Medical oncology (Northwood, London, England) · 2016Review
- A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.Clinical genitourinary cancer · 2015Article
- Non-invasive molecular imaging for preclinical cancer therapeutic development.British journal of pharmacology · 2013Review
- Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro.Prostate cancer and prostatic diseases · 2012Article
- mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.Endocrine-related cancer · 2012Article
- Emerging targeted therapies for castration-resistant prostate cancer.Frontiers in endocrinology · 2012Article
- Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2011Review
- Targeting autophagy during cancer therapy to improve clinical outcomes.Pharmacology & therapeutics · 2011Review
- Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.Clinical & experimental metastasis · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
introductionmTOR activity is increased in advanced prostate cancer (CaP) as a result of a high rate of PTEN mutations. RAD001 (Everolimus) is a new orally available mTOR inhibitor. The objective of our study was to evaluate the effects of RAD001 on the growth of CaP in the bone, both alone and in combination with docetaxel and zoledronic acid.
methodsC4-2 CaP cells were injected into tibiae of mice and the animals were treated with RAD001, docetaxel, and zoledronic acid alone or in combination. Histomorphometrical analysis, serum PSA measurements, bone mineral density (BMD), and microCT were used to determine the effects of treatment on tumor and bone.
resultsAll three agents alone decreased tumor volume, and RAD001 and docetaxel also decreased levels of serum PSA by 68% and 65%, respectively (both P < 0.01). Combinations of the agents were more effective in decreasing tumor volume than single agents. Three-drug treatment showed the greatest effect: 64% inhibition versus control (P < 0.01). Treatment with RAD001 interfered with the weight loss associated with growth of this tumor in the bone (non-RAD001 groups: 4.0% decrease in body weight, P = 0.0014; RAD001 groups: increase of 3.6% in body weight, P = 0.0037).
conclusionsRAD001 inhibited growth of C4-2 cells in bone, an effect augmented by addition of docetaxel and zoledronic acid. Moreover RAD001 had a significant impact on maintenance of body weight. RAD001 may hold promise for its effects on both metastatic CaP and the important syndrome of tumor cachexia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.